Agonist-selective signaling is determined by the receptor location within the membrane domains

被引:75
|
作者
Zheng, Hui [1 ]
Chu, Ji [1 ]
Qiu, Yu [1 ]
Loh, Horace H. [1 ]
Law, Ping-Yee [1 ]
机构
[1] Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA
关键词
lipid raft; opioid;
D O I
10.1073/pnas.0802253105
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The basis for agonist-selective signaling was investigated by using the mu-opioid receptor (MOR) as a model. In the absence of agonist, MOR located within the lipid raft domains, whereas etorphine, but not morphine, induced the translocation of MOR from lipid raft to nonraft domains, similar to the action of methyl-beta-cyclodextrin. The etorphine-induced MOR translocation required the dissociation of the receptor from G alpha i2 first and then the binding of beta-arrestin. In contrast, the low affinity of the morphine-MOR complex for beta-arrestin and the rebinding of G alpha i2 after GTP hydrolysis retained the complex within the lipid raft domains. Disruption of the MOR-G alpha i2 interaction, either by deleting the (RRITR280)-R-276 sequence of MOR or knocking down the level of G alpha i2, resulted in the translocation of MOR to the nonraft domains. In addition, lipid raft location of MOR was critical for G protein-dependent signaling, such as etorphine- and morphine-mediated inhibition of adenylyl cyclase activity and morphine-induced ERK phosphorylation, whereas beta-arrestin-dependent, etorphine-induced ERK phosphorylation required MOR to translocate into the nonraft domains. Thus, agonist-selective signaling is regulated by the location of MOR, which is determined by interactions of MOR with G proteins and beta-arrestin.
引用
收藏
页码:9421 / 9426
页数:6
相关论文
共 50 条
  • [1] Agonist-Selective Signaling of G Protein-Coupled Receptor: Mechanisms and Implications
    Zheng, Hui
    Loh, Horace H.
    Law, Ping-Yee
    IUBMB LIFE, 2010, 62 (02) : 112 - 119
  • [2] Structural determinants of agonist-selective signaling at the sst2A somatostatin receptor
    Nagel, F.
    Schulz, S.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2010, 381 : 11 - 11
  • [3] Structural Determinants of Agonist-Selective Signaling at the sst2A Somatostatin Receptor
    Nagel, Falko
    Doll, Christian
    Poell, Florian
    Kliewer, Andrea
    Schroeder, Helmut
    Schulz, Stefan
    MOLECULAR ENDOCRINOLOGY, 2011, 25 (05) : 859 - 866
  • [4] Agonist-Selective Signaling of μ-Opioid Receptors in T Lymphocytes
    Kraus, J.
    Boerner, C.
    Lanciotti, S.
    Koch, T.
    Hoellt, V
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2012, 385 : 48 - 48
  • [5] COMP 29-Opioid agonist-selective signaling.
    Law, Ping Y.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2008, 236
  • [6] Agonist-selective endocytosis of mu opioid receptor by neurons in vivo
    Sternini, C
    Spann, M
    Anton, B
    Keith, DE
    Bunnett, NW
    vonZastrow, M
    Evans, C
    Brecha, NC
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (17) : 9241 - 9246
  • [7] Agonist-selective phosphorylation of the human sst3 somatostatin receptor determined by phosphosite-specific antibodies
    Lehmann, A.
    Schulz, S.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2015, 388 : S7 - S7
  • [8] Agonist-selective internalization of the human 5-HT2A receptor
    Buchborn, T.
    Kahl, E.
    Hoellt, V
    Koch, T.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2012, 385 : 17 - 17
  • [9] Agonist-selective patterns of μ-opioid receptor phosphorylation revealed by phosphosite-specific antibodies
    Doll, C.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2011, 383 : 33 - 33
  • [10] Agonist-selective mechanisms of μ-opioid receptor desensitization in human embryonic kidney 293 cells
    Johnson, Elizabeth A.
    Oldfield, Sue
    Braksator, Ellen
    Gonzalez-Cuello, Ana
    Couch, Daniel
    Hall, Kellie J.
    Mundell, Stuart J.
    Bailey, Chris P.
    Kelly, Eamonn
    Henderson, Graeme
    MOLECULAR PHARMACOLOGY, 2006, 70 (02) : 676 - 685